^
Association details:
| Biomarker: | PD-L1-L |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
524 Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer receiving immune check-point inhibitors – applicability and potential caveats
Published date:
11/08/2022
Excerpt:
The median overall survival was 26 months in sPD-L1(low), 15 months in sPD-L1(medium), and 9 months in sPD-L1(high). The difference between these was statistically significant (p=0.04, logrank test)….sPD-L1 has potential as a prognostic marker in NSCLC receiving anti-PD-1 therapy.
DOI:
10.1136/jitc-2022-SITC2022.0524
